📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
88 announcements match the current filters (relevance ≥ 5).
Zydus Lifesciences Extends Sterling Biotech API Acquisition Deadline to Sept 30, 2026
Zydus Lifesciences has announced a further extension for the acquisition of Sterling Biotech Limited's (SBL) API business. Originally expected to close by December 31, 2024, the deadline was first moved to June 2026 and has now been extended to September 30, 2026. The delay is attributed to SBL completing certain conditions precedent specified in the Business Transfer Agreement. While the deal value was not disclosed in this update, the repeated delays indicate procedural or regulatory hurdles at the target entity.
Confidence: HIGH
What changedThe completion timeline for the acquisition of Sterling Biotech's API business has been pushed back from June 30, 2026, to September 30, 2026.
Why it mattersDelays in M&A completion postpone the realization of operational synergies and backward integration benefits, although the company's strong OPM of 35.5% suggests current operations remain robust.
New Closing Date: September 30, 2026Previous Extended Date: June 30, 2026Original Closing Date: December 31, 2024TTM Revenue: ₹19,316 CrMarket Cap: ₹1,12,217 Cr
📅 Short termNeutral. The market is likely to view this as a procedural delay rather than a deal cancellation, given the long-term nature of the previous extension.
📈 Long termThe acquisition remains part of Zydus's strategy to scale its API and MedTech presence, but repeated timeline shifts may raise concerns regarding the target's readiness.
⚠ Risk flags
- Execution delay
- Regulatory/Conditions Precedent hurdles at target company
- Integration risk
Key Highlights
Closing date for Sterling Biotech API acquisition extended to September 30, 2026
Original transaction completion was targeted for December 31, 2024, representing a 21-month delay
Extension necessitated by pending conditions precedent (CPs) to be fulfilled by Sterling Biotech
Zydus maintains a TTM revenue of ₹19,316 Cr, providing significant financial cushion for such acquisitions
The acquisition is part of a broader strategy to strengthen the bulk drug (API) and formulation portfolio
👀 What to Watch
Investors should monitor for the final completion notice by September 2026 and watch for any potential impact on the company's backward integration strategy for its formulation business.
Zydus Lifesciences to Form 50:50 JV in Sri Lanka with $20M Investment Commitment
Zydus Lifesciences has entered into a 50:50 joint venture with Sunshine Healthcare Lanka Limited to establish a new pharmaceutical manufacturing facility in Sri Lanka. The project involves a total investment commitment of over USD 20 million, with Zydus contributing up to USD 5 million for its equity stake. The facility, located in the Horana Export Processing Zone, aims to reduce Sri Lanka's import dependence while leveraging Zydus's manufacturing expertise and Sunshine's local distribution network. Zydus will maintain significant governance control, including the right to appoint the Chairperson with a casting vote.
Key Highlights
Establishment of Zydus Sunshine Lifesciences as a 50:50 joint venture in Sri Lanka
Total project investment commitment exceeding USD 20 million to build a state-of-the-art facility
Zydus to invest up to USD 5 million in cash for its 50% shareholding
Strategic focus on manufacturing pharmaceutical products for Sri Lanka's retail market
Governance structure allows Zydus to appoint the Chairperson with a casting vote on most matters
👀 What to Watch
Investors should view this as a positive strategic expansion that strengthens Zydus's footprint in the South Asian market. While the immediate financial impact is modest, the move builds long-term manufacturing capabilities and supply chain resilience in a key neighboring geography.
Zydus Lifesciences Extinguishes 87.3 Lakh Shares Post INR 1,100 Crore Buyback
Zydus Lifesciences has completed the formal extinguishment of 87,30,158 equity shares following its INR 1,100 crore buyback program. The shares were repurchased at a price of INR 1,260 per share via the tender offer route. This action has reduced the company's total outstanding equity from 100.62 crore shares to 99.75 crore shares. The reduction in the equity base is a positive move for shareholders as it typically leads to an improvement in Earnings Per Share (EPS) and Return on Equity (ROE).
Key Highlights
Extinguished 87,30,158 fully paid-up equity shares of face value INR 1 each
Buyback completed at a price of INR 1,260 per share for a total outlay of INR 1,100 crore
Total issued share capital reduced from 100,62,33,990 to 99,75,03,832 equity shares
Promoter and Promoter Group shareholding marginally increased from 74.99% to 75.01% post-buyback
👀 What to Watch
The completion of the buyback and share extinguishment is a positive signal of management's commitment to returning capital to shareholders. Investors should remain invested as the reduced share count will likely enhance future valuation metrics.
Zydus Lifesciences Completes Acquisition of Assertio Holdings for USD 166.33 Million
Zydus Lifesciences has finalized the acquisition of US-based Assertio Holdings Inc. through its subsidiary Zara Merger Sub Inc., making it a wholly owned subsidiary. The total cash consideration for the deal is USD 166.33 million, paid at USD 23.50 per share. This acquisition integrates Assertio's specialty oncology portfolio, specifically the USFDA-approved biologic ROLVEDON®, which reported an adjusted turnover of USD 68.23 million in 2025. Consequently, Assertio has been delisted from the Nasdaq Global Market.
Key Highlights
Acquisition of 100% stake in Nasdaq-listed Assertio Holdings Inc. for USD 166.33 million.
Cash offer price of USD 23.50 per share on a fully diluted basis.
Acquisition includes ROLVEDON®, a BLA-approved biologic for febrile neutropenia with USD 68.23 million in 2025 turnover.
Strategic expansion into the US specialty oncology supportive care market.
Assertio has officially become a wholly owned subsidiary and ceased trading on Nasdaq.
👀 What to Watch
Investors should monitor the integration of Assertio's oncology portfolio and the subsequent impact on Zydus's US revenue margins. The acquisition of a BLA-approved biologic is a significant value-add for the company's specialty pipeline.
Zydus Lifesciences Completes Acquisition of Assertio Holdings at $23.50 Per Share
Zydus Lifesciences has successfully completed its cash tender offer for Assertio Holdings, Inc. (Nasdaq: ASRT) at a price of $23.50 per share. Approximately 66.32% of Assertio's outstanding shares, totaling 4,286,488 shares, were validly tendered by the June 15, 2026 deadline. The company is now proceeding with a merger to acquire the remaining shares at the same price, making Assertio a wholly-owned subsidiary. Following the completion of this merger, Assertio will be delisted from the Nasdaq Global Market.
Key Highlights
Acquisition of Assertio Holdings completed via a cash tender offer at $23.50 per share.
Total of 4,286,488 shares (66.32% of outstanding stock) were validly tendered and accepted.
Assertio will become a wholly-owned subsidiary of Zydus Lifesciences following the final merger step.
The target company will be delisted from the Nasdaq Global Market post-acquisition.
Zydus expects to promptly pay for all tendered shares as of June 16, 2026.
👀 What to Watch
Investors should monitor the integration of Assertio's portfolio into Zydus's US operations, as this acquisition is expected to strengthen their specialty pharmaceutical presence and impact long-term revenue growth.
Zydus Lifesciences Receives USFDA Warning Letter for Baddi Manufacturing Facility
Zydus Lifesciences has received a Warning Letter from the USFDA regarding its formulation manufacturing facility in Baddi, Himachal Pradesh. The letter is based on technical observations concerning purified talc compliance with USP requirements following a records request under section 704(a)(4). Although the facility received a Voluntary Action Indicated (VAI) status after its last inspection in August 2025, this Warning Letter represents an escalation in regulatory oversight. The company stated that it does not expect any impact on current operations or supplies from the site.
Key Highlights
Warning Letter issued by USFDA for the Baddi formulation manufacturing facility in Himachal Pradesh.
Observations pertain to purified talc failing to meet United States Pharmacopeia (USP) requirements.
The regulatory action resulted from a records review (Section 704(a)(4)) rather than a new on-site inspection.
Facility was previously classified as Voluntary Action Indicated (VAI) following an August 2025 inspection.
Management believes the letter will not impact current manufacturing operations or existing supplies.
👀 What to Watch
Investors should monitor the timeline for remediation and potential delays in new product approvals from the Baddi site. While current revenue is protected, a Warning Letter typically increases compliance costs and regulatory risk.
Zydus Lifesciences Announces ₹1,100 Crore Buyback at ₹1,260 Per Share
Zydus Lifesciences has issued a Letter of Offer for a ₹1,100 crore share buyback via the tender offer route. The company will repurchase up to 87,30,158 equity shares at a fixed price of ₹1,260 per share, which represents a premium to recent trading prices. The buyback is scheduled to open on June 4, 2026, and close on June 10, 2026, following the record date of May 29, 2026. This move aims to return surplus cash to shareholders and improve financial ratios like Earnings Per Share (EPS).
Key Highlights
Buyback of up to 87,30,158 shares at ₹1,260 per share, totaling ₹1,100 crore
Small shareholder entitlement ratio set at 5 shares for every 49 shares held (approx. 10.2%)
General category entitlement ratio set at 7 shares for every 937 shares held (approx. 0.75%)
Buyback size represents 3.84% of consolidated paid-up capital and free reserves as of March 31, 2026
Tendering period runs from June 4, 2026, to June 10, 2026
👀 What to Watch
Eligible shareholders as of the May 29 record date should consider tendering their shares to capitalize on the premium buyback price. Small shareholders should note their significantly higher entitlement ratio compared to the general category.
Zydus Lifesciences to Buy Back Shares Worth ₹1,100 Crore at ₹1,260 Per Share
Zydus Lifesciences has announced a ₹1,100 crore buyback via the tender offer route at a price of ₹1,260 per share. The company intends to repurchase up to 87,30,158 equity shares, representing 0.87% of its total paid-up capital. Small shareholders have a significantly higher entitlement ratio of approximately 10.2% (5 shares for every 49 held) compared to the general category. The buyback window is scheduled to open on June 4, 2026, and close on June 10, 2026.
Key Highlights
Buyback price of ₹1,260 per share represents a premium over the current market price.
Total buyback size is capped at ₹1,100 crore, representing 3.84% of consolidated free reserves.
Entitlement ratio for small shareholders is 5:49, while the general category is 7:937.
The buyback involves 87.3 lakh shares, which is 0.87% of the total equity base.
Tendering period is set for June 4 to June 10, 2026, following the May 29 record date.
👀 What to Watch
Eligible shareholders who held stock on the May 29 record date should consider tendering their shares to capitalize on the premium buyback price. Small shareholders should particularly note the favorable 10.2% entitlement ratio.
Zydus Lifesciences Announces ₹1,100 Crore Buyback at ₹1,260 Per Share via Tender Offer
Zydus Lifesciences is initiating a buyback of up to 87,30,158 equity shares at a price of ₹1,260 per share, representing a total outlay of ₹1,100 crore. The buyback will be conducted through the tender offer route, representing 3.84% of the company's consolidated free reserves. The offer opens on June 4, 2026, and closes on June 10, 2026, for shareholders who held stock as of the May 29, 2026 record date. Small shareholders benefit from a significantly higher entitlement ratio of approximately 10.2% compared to 0.75% for the general category.
Key Highlights
Buyback price of ₹1,260 per share is set at a premium to the current market price.
Total buyback size is capped at ₹1,100 crore, involving 0.87% of total paid-up equity shares.
Small shareholder entitlement ratio is 5 shares for every 49 shares held (approx. 10.2%).
General category entitlement ratio is 7 shares for every 937 shares held (approx. 0.75%).
The buyback window is scheduled from June 4, 2026, to June 10, 2026.
👀 What to Watch
Eligible shareholders should consider tendering their shares to benefit from the premium buyback price, particularly small shareholders with higher entitlement. Investors should ensure their tender forms are submitted before the June 10, 2026 deadline.
Zyduslife's Saroglitazar NDA for PBC Gets US FDA Priority Review; PDUFA Date Nov 27, 2026
Zydus Lifesciences' subsidiary, Zydus Therapeutics, has received US FDA Priority Review for its New Drug Application (NDA) for Saroglitazar, targeting Primary Biliary Cholangitis (PBC). The Phase 3 EPICS-III trial demonstrated a significant 56.7% biochemical response rate compared to just 9.8% for the placebo group. The US FDA has set a PDUFA action date for November 27, 2026, with a potential commercial launch planned for Q4 FY27. This development marks a major milestone in Zydus's innovation pipeline for rare liver diseases in the high-value US market.
Key Highlights
US FDA assigned a PDUFA target action date of November 27, 2026, for Saroglitazar's NDA.
Phase 3 trial met primary endpoint with 56.7% biochemical response vs 9.8% for placebo (p < 0.001).
Saroglitazar reduced mean alkaline phosphatase (ALP) levels by 33.5% compared to a 6.5% increase in placebo.
Management plans to launch the drug in the United States in Q4 of FY 2026-27 if approved.
Secondary endpoint showed significant reduction in pruritus (itching) at Week 24 with a treatment difference of -3.2.
👀 What to Watch
Investors should view this as a significant positive for Zydus's specialty R&D pipeline, potentially opening a high-margin US market segment. Monitor the PDUFA date in late November 2026 for final approval news which would be a major catalyst.
Zydus Lifesciences Hikes Buyback Price to ₹1,260 per Share; Reduces Share Count
Zydus Lifesciences has revised its buyback offer, increasing the offer price from ₹1,150 to ₹1,260 per equity share. Due to the price hike, the maximum number of shares to be bought back has been reduced to 87,30,158, which accounts for 0.87% of the company's total paid-up equity capital. The buyback will proceed via the tender offer route, allowing shareholders to participate on a proportionate basis. This update was officially published as an addendum to the initial announcement on May 28, 2026.
Key Highlights
Buyback price increased to ₹1,260 from the previously announced ₹1,150 per share
Maximum buyback size adjusted to 87,30,158 equity shares (0.87% of total capital)
The transaction will be executed through the tender offer route on a proportionate basis
The revision follows the board's decision to enhance the offer value for shareholders
The face value of each equity share involved in the buyback is ₹1
👀 What to Watch
Shareholders should consider the 9.5% increase in the buyback price as a positive valuation signal. Monitor the record date to participate in the tender offer if the market price remains below ₹1,260.
Zydus Lifesciences Hikes Buyback Price to INR 1,260 per Share; Total Size INR 1,100 Cr
Zydus Lifesciences has announced an upward revision in its buyback price to INR 1,260 per share, up from the previously announced INR 1,150. While the total buyback size remains unchanged at INR 1,100 crore, the number of shares to be repurchased has been reduced to 87,30,158. This represents approximately 0.87% of the company's total paid-up equity share capital. The buyback will be executed via the tender offer route, providing a higher exit premium for participating shareholders.
Key Highlights
Buyback price revised upwards to INR 1,260 per share from the earlier INR 1,150.
Maximum number of shares to be bought back reduced to 87,30,158 to maintain total outlay.
Total aggregate buyback amount remains fixed at INR 1,100 crore.
The buyback represents 0.87% of the total number of equity shares in the paid-up share capital.
The process will be conducted through the tender offer route on a proportionate basis.
👀 What to Watch
Investors should consider tendering their shares to benefit from the increased offer price, which likely offers a significant premium over the current market price. Monitor the official record date to ensure eligibility for the tender process.
Zydus Lifesciences Receives US FDA Priority Review for Saroglitazar NDA; PDUFA Date Nov 27, 2026
Zydus Lifesciences' subsidiary, Zydus Therapeutics, has achieved a significant regulatory milestone with the US FDA granting Priority Review to its New Drug Application (NDA) for Saroglitazar. The drug is intended for the treatment of Primary Biliary Cholangitis (PBC), targeting patients who are either intolerant to or have an inadequate response to the standard UDCA treatment. The US FDA has assigned a PDUFA target action date of November 27, 2026, which accelerates the potential launch timeline. This development underscores the company's innovation capabilities and its focus on high-value specialty therapeutics in the US market.
Key Highlights
US FDA grants Priority Review for Saroglitazar NDA for the treatment of Primary Biliary Cholangitis (PBC).
Prescription Drug User Fee Act (PDUFA) target action date is set for November 27, 2026.
The drug aims to serve as both a combination therapy with UDCA and a monotherapy for intolerant patients.
Priority Review status indicates the drug's potential to provide significant improvements in treatment safety or effectiveness.
Saroglitazar is a key asset in Zydus's global innovation-led healthcare portfolio.
👀 What to Watch
Investors should view this as a major positive for the company's long-term growth and innovation pipeline. Maintain a positive outlook on the stock, keeping a close watch on further regulatory updates leading up to the November 2026 PDUFA date.
Zydus Lifesciences Q4 FY26: Net Profit up 15% to ₹15.9B; EBITDA Margins hit record 33.7%
Zydus Lifesciences delivered a robust Q4 FY26 performance with consolidated revenue growing 16% YoY to ₹75.9 billion and adjusted net profit rising 15% to ₹15.9 billion. The company achieved its highest-ever operating margins, with Q4 EBITDA margins expanding to 33.7% due to a strong product mix and specialty portfolio traction. Growth was broad-based, with India formulations rising 15% and international markets surging 45% YoY. The management is aggressively pivoting towards high-margin specialty oncology and medical devices through strategic acquisitions like Assertio and Amplitude Surgical.
Key Highlights
FY26 consolidated revenue reached ₹271.5 billion, up 17% YoY, with a record EBITDA of ₹84.8 billion.
India branded formulations grew 15% YoY, outperforming the market, with the chronic portfolio share rising to 46.3%.
International markets formulations grew 45% YoY to ₹8 billion, while Consumer Wellness surged 61% to ₹14.6 billion.
Launched world's first biosimilar of Nivolumab (Tishtha) and India's first indigenous Aflibercept biosimilar (Anyra).
Maintained a strong balance sheet with a Net Debt to EBITDA ratio of 0.5x despite significant inorganic investments.
👀 What to Watch
Investors should focus on the company's successful margin expansion and its strategic shift toward specialty oncology and rare diseases. The stock remains a high-conviction play in the pharma sector given its diversified revenue streams and disciplined capital allocation.
Zydus Lifesciences Announces ₹1,100 Crore Share Buyback at ₹1,150 Per Share
Zydus Lifesciences has issued a public announcement for the buyback of up to 95,65,217 equity shares through the tender offer route. The buyback price is set at ₹1,150 per share, representing a total commitment of up to ₹1,100 crores. This corporate action aims to return surplus cash to shareholders on a proportionate basis. The announcement follows the Board's approval on May 19, 2026, and complies with SEBI Buy-Back Regulations.
Key Highlights
Buyback of up to 95,65,217 fully paid-up equity shares of face value ₹1 each
Buyback price fixed at ₹1,150 per share payable in cash
Total aggregate buyback amount not to exceed ₹1,100 crores
Execution via the tender offer route on a proportionate basis for eligible shareholders
👀 What to Watch
Investors should monitor the upcoming record date to determine eligibility and evaluate the premium of the ₹1,150 offer price against the current market price for potential tendering.
Zydus Lifesciences Approves ₹1,100 Crore Buyback at ₹1,150 Per Share
Zydus Lifesciences has approved a share buyback of up to 95,65,217 equity shares at a price of ₹1,150 per share, representing a total outlay of ₹1,100 crores. The buyback will be conducted through the tender offer route, making it accessible to all shareholders holding shares as of the record date, May 29, 2026. The buyback size represents 3.84% of the company's consolidated free reserves and paid-up capital as of March 31, 2026. This capital return initiative is expected to support the stock price and improve earnings per share.
Key Highlights
Buyback price fixed at ₹1,150 per share, representing a premium over current market levels.
Total buyback size capped at ₹1,100 crores, excluding taxes and transaction costs.
Up to 95,65,217 shares (0.95% of total equity) to be repurchased via tender offer.
Record date for eligibility is set for Friday, May 29, 2026.
15% of the buyback is reserved for small shareholders as per SEBI regulations.
👀 What to Watch
Investors should monitor the stock price relative to the ₹1,150 offer price and ensure they hold shares by the May 29 record date if they wish to participate in the tender offer.
Zydus Lifesciences Promoters to Participate in Rs 1,100 Cr Buyback at Rs 1,150/Share
Zydus Lifesciences has confirmed that its promoter group intends to participate in the recently approved share buyback. The company will repurchase up to 95,65,217 shares, which accounts for 0.95% of the total paid-up equity capital. The buyback is priced at INR 1,150 per share, involving a total cash outlay of up to INR 1,100 crores. This process will be executed via the tender offer route, allowing all shareholders, including promoters, to participate proportionately.
Key Highlights
Buyback price set at INR 1,150 per share, representing a significant premium to recent trading prices.
Total buyback size capped at INR 1,100 crores for up to 95,65,217 equity shares.
Promoter group has formally communicated their intention to tender their shares in the offer.
The buyback represents 0.95% of the total paid-up equity share capital of the company.
The transaction will be conducted through the tender offer route on a proportionate basis as per SEBI regulations.
👀 What to Watch
Investors should monitor the record date and compare the buyback price of INR 1,150 with the market price to assess the potential for tendering shares, particularly in the retail category which often has a higher acceptance ratio.
Zydus Lifesciences Declares Re. 1 Final Dividend; Sets July 24, 2026 as Record Date
Zydus Lifesciences has recommended a final dividend of Re. 1 per equity share, representing 100% of the face value for the financial year ended March 31, 2026. The Board has fixed July 24, 2026, as the record date to determine shareholder eligibility for this payout. The dividend is subject to shareholder approval at the 31st Annual General Meeting scheduled for August 11, 2026. If approved, the company plans to distribute the dividend payment on or around August 14, 2026.
Key Highlights
Final dividend of Re. 1 per equity share (100% of face value) for FY26.
Record date for dividend entitlement fixed as July 24, 2026.
31st Annual General Meeting (AGM) scheduled for August 11, 2026.
Dividend payment expected to be processed on or around August 14, 2026.
👀 What to Watch
Investors seeking to benefit from the dividend should ensure they hold the stock before the ex-dividend date, typically one day prior to the July 24 record date. The dividend yield should be assessed relative to the current market price for total return expectations.
Zydus Lifesciences Declares Re. 1 Final Dividend; Sets July 24 as Record Date
Zydus Lifesciences has recommended a final dividend of Re. 1 per equity share (100% of face value) for the financial year ended March 31, 2026. The company has fixed July 24, 2026, as the record date to identify eligible shareholders for this payout. The dividend is subject to shareholder approval at the Annual General Meeting scheduled for August 11, 2026, with payment expected around August 14, 2026.
Key Highlights
Final dividend of Re. 1 per equity share of face value Re. 1 (100%)
Record date for dividend entitlement is fixed as July 24, 2026
31st Annual General Meeting (AGM) scheduled for August 11, 2026
Dividend payment expected to be processed on or around August 14, 2026
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the ex-dividend date, which typically falls one business day before the July 24 record date.
Zydus Life Q4 Net Profit Up 15%, Announces ₹1,100 Cr Buyback at 16% Premium
Zydus Lifesciences reported a strong Q4 FY26 with revenue growing 16.2% YoY to ₹75,870 mn and adjusted net profit rising 14.6% to ₹15,929 mn. The company's EBITDA margins expanded by 110 bps to 33.7%, driven by robust performance in India formulations and a 61% surge in Consumer Wellness. A major highlight for shareholders is the board's approval of an ₹11,000 mn share buyback at ₹1,150 per share, representing a 16% premium. Furthermore, the company is strengthening its US specialty presence through the $166 mn acquisition of Assertio Holdings.
Key Highlights
Q4 FY26 Revenue grew 16.2% YoY to ₹75,870 mn; FY26 Revenue up 16.8% to ₹2,71,484 mn
Adjusted Net Profit for Q4 rose 14.6% YoY to ₹15,929 mn with EBITDA margins improving to 33.7%
Approved ₹11,000 mn share buyback at ₹1,150 per share, a 16% premium to the closing price of May 18, 2026
India Formulations business grew 14% YoY, while Consumer Wellness surged 61% YoY in Q4
Acquisition of US-based Assertio Holdings for $166 mn to strengthen specialty and oncology portfolio
👀 What to Watch
Investors should benefit from the premium buyback and strong margin expansion, which signals high management confidence. The strategic shift toward US specialty products via the Assertio acquisition helps mitigate pricing pressures in the US generics market.
